MSI prediction model construction method based on immune-related genes

Abstract

The invention relates to an MSI prediction model construction method based on immune-related genes. The method comprises the following steps: collecting and constructing a training set and a verification set of an immune-related MSI prediction model irMSIs from a cancer genome map database; selecting immune related genes from the immunology database, and screening differential genes from the immune related genes; according to the screened differential genes, constructing an immune-related MSI prediction model irMSIs through an LASSO logistic regression algorithm; and verifying the prognosis risk by using the immune-related MSI prediction model irMSIs. The invention provides the application of the immune related gene in MSI state prediction, a group of characteristic genes capable of stably predicting MSI in digestive tract tumors, especially colon cancer, is found in combination with the immune related gene, and the prognosis risk of the colon cancer can be well predicted.

Description

technical field [0001] The invention relates to the technical field of biological information, in particular to a method for constructing an MSI prediction model related to colon cancer based on immune-related genes. Background technique [0002] In recent years, tumor immunotherapy for colon cancer has been considered as a treatment method that cannot be ignored, and its focus is to achieve the efficacy of identifying, controlling and eliminating tumors by activating the body's immune system. Drugs targeting immune checkpoint inhibitors (ICIs), such as cytotoxic T-lymphatic system-associated protein 4 (CTLA-4) monoclonal antibody, inhibitor of programmed death protein and its ligand (PD-1 / PD-L1 ) monoclonal antibodies, etc., have brought new hope for the treatment of various tumors, including advanced melanoma, non-small cell lung cancer and bladder cancer. Patients with colon cancer can also benefit from immunotherapy. At present, the US FDA has approved PD-1 immunotherap...

AI Technical Summary

Problems solved by technology

Compared with MSS / MSI-L patients, MSI-H colon cancer patients have a significant survival advantage, with poorer clinical performance, but significantly prolonged overall survival and disease-free survival

[0005] Therefore, immune-related genes play a vital role in the occurrence and development of colon cancer. The traditional methods for detecting MSI are mainly immunohistochemistry (IHC) and polymerase chain reaction (PCR). It needs to be carried out in large medical institutions, and the cost is high and the operation is cumbersome. It is difficult to promote to every patient in clinical practice. Therefore, it is impossible to provide timely ICIs treatment for a large number of potentially immunotherapy-sensitive patients, thus losing the chance of clinical benefit

Images